Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1999; 34:62-69
© 1999 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by French, J. K.
Right arrow Articles by White, H. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by French, J. K.
Right arrow Articles by White, H. D.

CLINICAL STUDIES

Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks

John K. French, MB, PhDa, Thomas A. Hyde, MBa, Hitesh Patel, MBa, David J. Amos, MBa, Stephanie C. McLaughlin, PhDa, Bruce J. Webber, DSR (Diagnostic)a and Harvey D. White, MB, DSca

a Cardiovascular Research Unit, Cardiology Department, Green Lane Hospital, Auckland, New Zealand

Manuscript received January 14, 1999; revised manuscript received February 23, 1999, accepted March 24, 1999.

Reprint requests and correspondence: Dr. John French, Cardiology Department, Green Lane Hospital, Private Bag 92 189, Auckland 1030, New Zealand
johnf{at}ahsl.co.nz

OBJECTIVES

The purpose of this study was to determine whether the mortality benefit of intravenous streptokinase administered within 4 h of the onset of acute myocardial infarction is maintained at 12 years, and whether Thrombolysis in Myocardial Infarction (TIMI) flow grades independently influence late survival.

BACKGROUND

Treatment with reperfusion therapies and achievement of TIMI 3 flow are associated with increased short- and medium-term survival after infarction. Whether infarct artery flow independently influences survival more than five years after infarction is unknown.

METHODS

The late survival of patients randomized to receive either streptokinase (1,500,000 IU over 30 to 60 min) or a matching placebo within 4 h of symptom onset in 1984–1986 was determined. Angiography was performed in surviving patients at three to four weeks, and TIMI flow grades were assessed blind to randomization and outcomes. The late vital status was determined in 99% of patients.

RESULTS

Patients randomized to receive streptokinase (n = 107) had improved survival compared with those randomized to placebo (n = 112) at five years (84% vs. 70%; p = 0.023) and 12 years (66% vs. 51%; p = 0.022). At five years 94% of patients with TIMI grade 3 flow, 81% of those with TIMI grade 2 flow and 72% of those with TIMI grade 0–1 flow survived (p = 0.005). At 12 years 72% of patients with TIMI 3, 67% of those with TIMI 2 and 54% of those with TIMI 0–1 flow survived (p = 0.023). Multivariate analysis identified the ejection fraction (p = 0.014), exercise duration (p = 0.013) and TIMI 3 flow (p = 0.04 compared with TIMI 0–2 flow) as important factors for five-year survival. At 12 years multivariate predictors of late survival were the ejection fraction (p = 0.006), exercise duration (p = 0.003) and myocardial score (p = 0.013). The end-systolic volume index was similar to the ejection fraction as a predictor of survival at five and 12 years.

CONCLUSIONS

The survival benefits of streptokinase persist for 12 years after infarction. TIMI flow at three to four weeks is an independent predictor of five-year survival.

Abbreviations and Acronyms
  ECSG = European Cooperative Study Group
  TIMI = Thrombolysis in Myocardial Infarction




This article has been cited by other articles:


Home page
NEJMHome page
A. H. Gershlick, A. Stephens-Lloyd, S. Hughes, K. R. Abrams, S. E. Stevens, N. G. Uren, A. de Belder, J. Davis, M. Pitt, A. Banning, et al.
Rescue Angioplasty after Failed Thrombolytic Therapy for Acute Myocardial Infarction
N. Engl. J. Med., December 29, 2005; 353(26): 2758 - 2768.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. T. van Domburg, K. Sonnenschein, R. Nieuwlaat, O. Kamp, C. J. Storm, J. J. Bax, and M. L. Simoons
Sustained Benefit 20 Years After Reperfusion Therapy in Acute Myocardial Infarction
J. Am. Coll. Cardiol., July 5, 2005; 46(1): 15 - 20.
[Abstract] [Full Text] [PDF]


Home page
BMJHome page
D. Smith
Primary angioplasty should be first line treatment for acute myocardial infarction: FOR
BMJ, May 22, 2004; 328(7450): 1254 - 1256.
[Full Text] [PDF]


Home page
CirculationHome page
L. N. Graham, P. A. Smith, R. J. Huggett, J. B. Stoker, A. F. Mackintosh, and D. A.S.G. Mary
Sympathetic Drive in Anterior and Inferior Uncomplicated Acute Myocardial Infarction
Circulation, May 18, 2004; 109(19): 2285 - 2289.
[Abstract] [Full Text] [PDF]


Home page
Br Med BullHome page
A H Gershlick
The acute management of myocardial infarction
Br. Med. Bull., October 1, 2001; 59(1): 89 - 112.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
K S Channer and P J Pugh
Interfering with healing: the benefits of intervention during acute myocardial infarction
Heart, June 1, 2001; 85(6): 620 - 622.
[Full Text]


Home page
J Am Coll CardiolHome page
J. K. French, T. A. Hyde, I. T. Straznicky, J. Andrews, M. Lund, D. J. Amos, A. Zambanini, C. J. Ellis, B. J. Webber, S. C. McLaughlin, et al.
Relationship between corrected TIMI frame counts at three weeks and late survival after myocardial infarction
J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1516 - 1524.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement